MCL1 and Miyoshi myopathy: Notably, U266/Mcl-1 cells were significantly more resistant to bortezomib (5 nM) than their empty-vector counterparts (P < 0.01; Figure 1C, lower panel), indicating that Mcl-1 down-regulation may enhance bortezomib sensitivity in MM.